Loading...
XNASNKTR
Market cap189mUSD
Jan 10, Last price  
1.03USD
1D
-9.65%
1Q
-24.26%
Jan 2017
-91.61%
Name

Nektar Therapeutics

Chart & Performance

D1W1MN
XNAS:NKTR chart
P/E
—
P/S
2.11
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
1.07%
Rev. gr., 5y
-40.35%
Revenues
90m
-2.10%
114,270,000126,279,000217,718,000273,027,00090,185,00071,931,000159,039,00071,480,00081,191,000148,921,000200,707,000230,784,000165,436,000307,711,0001,193,323,000114,617,000152,915,000101,907,00092,055,00090,122,000
Net income
-276m
L-25.03%
-101,886,000-185,111,000-154,761,000-32,761,000-34,336,000-102,519,000-37,938,000-133,978,000-171,855,000-162,013,000-53,916,000-81,177,000-153,524,000-96,692,000681,313,000-440,667,000-444,440,000-523,837,000-368,198,000-276,056,000
CFO
-193m
L-36.64%
-78,142,000-77,998,000-92,715,000146,302,000-145,782,00039,739,000-55,871,000-113,742,000-129,756,000-38,527,000-142,006,000-73,083,000-117,024,000-80,414,000718,214,000-328,681,000-313,287,000-412,660,000-304,007,000-192,606,000
Earnings
Mar 03, 2025

Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.
URL
https://www.nektar.com/
IPO date
May 03, 1994
Employees
216
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
90,122
-2.10%
92,055
-9.67%
Cost of revenue
228,223
332,291
Unusual Expense (Income)
NOPBT
(138,101)
(240,236)
NOPBT Margin
Operating Taxes
(200)
3,215
Tax Rate
NOPAT
(137,901)
(243,451)
Net income
(276,056)
-25.03%
(368,198)
-29.71%
Dividends
Dividend yield
Proceeds from repurchase of equity
30
758
BB yield
-0.03%
-0.18%
Debt
Debt current
38,518
18,667
Long-term debt
216,293
244,325
Deferred revenue
Other long-term liabilities
117,260
162,929
Net debt
(74,630)
(241,985)
Cash flow
Cash from operating activities
(192,606)
(304,007)
CAPEX
(865)
(5,676)
Cash from investing activities
139,564
365,835
Cash from financing activities
30
1,508
FCF
(111,415)
(151,802)
Balance
Cash
303,616
504,977
Long term investments
25,825
Excess cash
324,935
500,374
Stockholders' equity
(3,477,150)
(3,208,081)
Invested Capital
3,870,635
3,869,144
ROIC
ROCE
EV
Common stock shares outstanding
190,001
187,138
Price
0.57
-75.00%
2.26
-83.27%
Market cap
107,351
-74.62%
422,932
-82.92%
EV
32,721
180,947
EBITDA
(130,286)
(227,206)
EV/EBITDA
Interest
25,334
28,911
Interest/NOPBT